Trial Outcomes & Findings for GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) (NCT NCT02528357)
NCT ID: NCT02528357
Last Updated: 2021-05-18
Results Overview
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
141 participants
Primary outcome timeframe
Up to maximum 39 weeks
Results posted on
2021-05-18
Participant Flow
This was a 2 part study conducted across 4 countries. Part 1 was dose-escalation study to evaluate GSK3174998 monotherapy. Part 2 included dose-escalation cohorts of GSK3174998+pembrolizumab combination therapy (Comb. Th.) (Part 2A) and dose-expansion (Expan.) disease specific cohorts (Coh.) of GSK3174998 + pembrolizumab (Part 2B).
A total of 141 participants were enrolled in the study: 45 participants in Part 1 and 96 participants in Part 2 (74 in Part 2A+ 22 in Part 2B).
Participant milestones
| Measure |
Part 1: GSK3174998 0.003 mg/kg
Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.
|
Part 1: GSK3174998 0.01 mg/kg
Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.
|
Part 1: GSK3174998 0.03 mg/kg
Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 10.0 mg/kg
Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.
|
Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part1:Monotherapy(Up to Maximum 39weeks)
STARTED
|
1
|
1
|
8
|
10
|
10
|
4
|
7
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part1:Monotherapy(Up to Maximum 39weeks)
COMPLETED
|
1
|
0
|
6
|
9
|
6
|
2
|
5
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part1:Monotherapy(Up to Maximum 39weeks)
NOT COMPLETED
|
0
|
1
|
2
|
1
|
4
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
10
|
12
|
14
|
12
|
12
|
4
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
7
|
9
|
9
|
6
|
5
|
4
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
3
|
5
|
6
|
7
|
0
|
0
|
0
|
0
|
|
Part2B:Expan. Coh.(Up to Maximum 33 Wks)
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
8
|
5
|
|
Part2B:Expan. Coh.(Up to Maximum 33 Wks)
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
4
|
2
|
|
Part2B:Expan. Coh.(Up to Maximum 33 Wks)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
3
|
Reasons for withdrawal
| Measure |
Part 1: GSK3174998 0.003 mg/kg
Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.
|
Part 1: GSK3174998 0.01 mg/kg
Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.
|
Part 1: GSK3174998 0.03 mg/kg
Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 10.0 mg/kg
Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.
|
Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part1:Monotherapy(Up to Maximum 39weeks)
Lost to Follow-up
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part1:Monotherapy(Up to Maximum 39weeks)
Physician Decision
|
0
|
0
|
0
|
1
|
0
|
2
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part1:Monotherapy(Up to Maximum 39weeks)
Withdrawal by Subject
|
0
|
0
|
2
|
0
|
3
|
0
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part1:Monotherapy(Up to Maximum 39weeks)
Follow-up assessments removed (Protocol Amendment 4)
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
Investigator site closed
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
5
|
0
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
1
|
3
|
1
|
0
|
0
|
0
|
0
|
|
Part2A:Comb. Th. (Up to Maximum 105wks)
Follow-up assessments removed (Protocol Amendment 4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
3
|
4
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Part2B:Expan. Coh.(Up to Maximum 33 Wks)
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
|
Part2B:Expan. Coh.(Up to Maximum 33 Wks)
Follow-up assessments removed (Protocol Amendment 4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
3
|
Baseline Characteristics
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
Baseline characteristics by cohort
| Measure |
Part 1: GSK3174998 0.003 mg/kg
n=1 Participants
Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.
|
Part 1: GSK3174998 0.01 mg/kg
n=1 Participants
Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.
|
Part 1: GSK3174998 0.03 mg/kg
n=8 Participants
Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 10.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.
|
Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg
n=5 Participants
Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg
n=5 Participants
Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg
n=10 Participants
Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Total
n=141 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
18 to 64 years
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
8 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
8 Participants
n=36 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
6 Participants
n=136 Participants
|
5 Participants
n=44 Participants
|
2 Participants
n=667 Participants
|
76 Participants
n=15 Participants
|
|
Age, Customized
65 to 84 years
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=24 Participants
|
2 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
3 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
64 Participants
n=15 Participants
|
|
Age, Customized
>=85 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
|
Sex: Female, Male
Female
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
8 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
6 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
8 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
4 Participants
n=44 Participants
|
1 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Sex: Female, Male
Male
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
7 Participants
n=42 Participants
|
8 Participants
n=36 Participants
|
9 Participants
n=36 Participants
|
4 Participants
n=24 Participants
|
4 Participants
n=135 Participants
|
6 Participants
n=136 Participants
|
4 Participants
n=44 Participants
|
4 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · African American/African Heritage
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · Asian - Central/South Asian Heritage
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · Asian - East Asian Heritage
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
1 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · Asian - South East Asian Heritage
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · White - Arabic/North African Heritage
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · White - White/Caucasian/European Heritage
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
7 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
7 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
10 Participants
n=42 Participants
|
12 Participants
n=42 Participants
|
12 Participants
n=36 Participants
|
7 Participants
n=36 Participants
|
10 Participants
n=24 Participants
|
2 Participants
n=135 Participants
|
9 Participants
n=136 Participants
|
6 Participants
n=44 Participants
|
4 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
|
Race/Ethnicity, Customized
Race · Missing
|
NA Participants
n=5 Participants
|
NA Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
2 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
NA Participants
n=15 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population consisted of all participants who received at least one dose of GSK3174998.
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)
Any SAE
|
1 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
7 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
|
Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)
Any non-SAE
|
4 Participants
|
1 Participants
|
1 Participants
|
8 Participants
|
10 Participants
|
10 Participants
|
4 Participants
|
7 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Any SAE and Non-SAE
Any SAE
|
2 Participants
|
1 Participants
|
1 Participants
|
6 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
|
Part 2A: Number of Participants With Any SAE and Non-SAE
Any non-SAE
|
4 Participants
|
5 Participants
|
5 Participants
|
10 Participants
|
12 Participants
|
13 Participants
|
12 Participants
|
12 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Any SAE and Non-SAE
Any SAE
|
—
|
1 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any SAE and Non-SAE
Any non-SAE
|
—
|
9 Participants
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: 28 daysPopulation: All Treated Population
An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of \>7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of \>=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 28 daysPopulation: All Treated Population
An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of \>7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of \>=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With DLTs
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 28 daysPopulation: All Treated Population
An adverse event was considered as DLT if it was considered by the investigator to be clinically relevant and attributed (definitely, probably or possibly) to study treatment, occurred within the first 28 days of the treatment, and met 1 of the following criteria: Hematologic: Febrile neutropenia, Grade4 neutropenia of \>7days requiring Granulocyte colony-stimulating factor (G-CSF), Grade4 anemia of any duration, Grade4 thrombocytopenia of any duration or Grade3 thrombocytopenia with bleeding as described in National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4). Non-hematologic: Grade4 toxicity, Grade3 toxicity that cannot be controlled within 3days, Ocular toxicity of \>=Grade3 or of Grade2 requiring systemic steroids. Any other event results in permanent discontinuation of treatment during the first 4 weeks of treatment or any other event which in the judgment of the investigator and GlaxoSmithKline medical monitor is considered to be a DLT.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With DLTs
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the Study
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population
An adverse event is any untoward medical occurrence in a participant or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any adverse event leading to withdrawal from the study is presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Any Adverse Event Leading to Withdrawal From the Study
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population
Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Dose Reductions or Delay
Dose reduction
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Dose Reductions or Delay
Dose delay
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population
Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Dose Reductions or Delay
Dose reduction
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 2A: Number of Participants With Dose Reductions or Delay
Dose delay
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population
Number of participants who had any dose reduction or dose delay (GSK3174998) due to any reason have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Dose Reductions or Delay
Dose reduction
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Dose Reductions or Delay
Dose delay
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 39 weeksPopulation: All Treated Population
Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), leukocyte count (leuko.), lymphocyte count (Lymph.), neutrophil count (Neutro.) and platelet count (PC). The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Leuko. increased
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Leuko. decreased
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Hb decreased (anemia)
|
1 Participants
|
1 Participants
|
0 Participants
|
7 Participants
|
6 Participants
|
5 Participants
|
3 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Hb increased
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Lymph. decreased
|
3 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
3 Participants
|
6 Participants
|
1 Participants
|
5 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Lymph. increased
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Neutro. decreased
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
PC decreased
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 105 weeksPopulation: All Treated Population
Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Hb increased
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Leuko. increased
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Leuko. decreased
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Lymph. decreased
|
2 Participants
|
2 Participants
|
2 Participants
|
5 Participants
|
2 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Lymph. increased
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Neutro. decreased
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
PC decreased
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Hb decreased (anemia)
|
1 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
5 Participants
|
4 Participants
|
3 Participants
|
5 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 33 weeksPopulation: All Treated Population
Blood samples were collected for the analysis of following hematology parameters: Hb, leuko., Lymph., Neutro. and PC. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Hb decreased (anemia)
|
—
|
2 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Hb increased
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Leuko. increased
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Leuko. decreased
|
—
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Lymph. decreased
|
—
|
3 Participants
|
3 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Lymph. increased
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
Neutro. decreased
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology Parameters
PC decreased
|
—
|
1 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 39 weeksPopulation: All Treated Population
Blood samples were collected for the analysis of following liver function laboratory parameters: alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST) and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
ALT increased
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
ALP increased
|
2 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
1 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
AST increased
|
3 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
5 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
Bilirubin increased
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 105 weeksPopulation: All Treated Population
Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
ALT increased
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
ALP increased
|
1 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
4 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
AST increased
|
1 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
6 Participants
|
3 Participants
|
3 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
Bilirubin increased
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 33 weeksPopulation: All Treated Population
Blood samples were collected for the analysis of following liver function laboratory parameters: ALT, ALP, AST and bilirubin. The laboratory parameters were graded according to NCI-CTCAE version 4. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
ALT increased
|
—
|
2 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
ALP increased
|
—
|
3 Participants
|
4 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
AST increased
|
—
|
3 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory Parameters
Bilirubin increased
|
—
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 39 weeksPopulation: All Treated Population
SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: \<120 millimeter mercury (mmHg); Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: \>=160 mmHg. For DBP: Grade 0: \<80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: \>=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP
|
3 Participants
|
0 Participants
|
1 Participants
|
6 Participants
|
3 Participants
|
5 Participants
|
2 Participants
|
6 Participants
|
|
Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
DBP
|
2 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
5 Participants
|
5 Participants
|
2 Participants
|
2 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 105 weeksPopulation: All Treated Population
SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: \<120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: \>=160 mmHg. For DBP: Grade 0: \<80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: \>=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBP
SBP
|
1 Participants
|
2 Participants
|
4 Participants
|
8 Participants
|
6 Participants
|
6 Participants
|
7 Participants
|
7 Participants
|
|
Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBP
DBP
|
0 Participants
|
1 Participants
|
4 Participants
|
7 Participants
|
6 Participants
|
6 Participants
|
5 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 33 weeksPopulation: All Treated Population
SBP and DBP were graded using NCI-CTCAE version 4. For SBP: Grade 0: \<120 mmHg; Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: \>=160 mmHg. For DBP: Grade 0: \<80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: \>=100 mmHg. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Any grade increase is defined as an increase in NCI-CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with any grade increase have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBP
SBP
|
—
|
7 Participants
|
4 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBP
DBP
|
—
|
5 Participants
|
5 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 39 weeksPopulation: All Treated Population
Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: \<60 beats per minute \[bpm\]', normal HR: 60 to 100 bpm and high HR: \>100 bpm. If values were unchanged (example: increase to \>100 bpm to increase to \>100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)
Decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)
Change to normal or no change
|
2 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
|
Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)
Increase to high
|
2 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
6 Participants
|
6 Participants
|
1 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 105 weeksPopulation: All Treated Population
Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: \<60 bpm', normal HR: 60 to 100 bpm and high HR: \>100 bpm. If values were unchanged (example: increase to \>100 bpm to increase to \>100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Worst Case Change From Baseline in HR
Decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
|
Part 2A: Number of Participants With Worst Case Change From Baseline in HR
Change to normal or no change
|
4 Participants
|
5 Participants
|
4 Participants
|
7 Participants
|
6 Participants
|
8 Participants
|
8 Participants
|
6 Participants
|
|
Part 2A: Number of Participants With Worst Case Change From Baseline in HR
Increase to high
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 33 weeksPopulation: All Treated Population
Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in heart rate is presented. Data was categorized as: heart rate 'decrease to low', 'increase to high' and 'change to normal or no change'; where low HR: \<60 bpm', normal HR: 60 to 100 bpm and high HR: \>100 bpm. If values were unchanged (example: increase to \>100 bpm to increase to \>100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Worst Case Change From Baseline in HR
Decrease to low
|
—
|
2 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Worst Case Change From Baseline in HR
Change to normal or no change
|
—
|
4 Participants
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Worst Case Change From Baseline in HR
Increase to high
|
—
|
3 Participants
|
4 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 39 weeksPopulation: All Treated Population
Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: \<=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: \>=38 degrees Celsius. If values were unchanged (example: increase to \>=38 degrees Celsius to increase to \>=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature
Decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature
Change to normal or no change
|
4 Participants
|
1 Participants
|
1 Participants
|
8 Participants
|
8 Participants
|
9 Participants
|
3 Participants
|
7 Participants
|
|
Part 1: Number of Participants With Worst Case Change From Baseline in Body Temperature
Increase to high
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 105 weeksPopulation: All Treated Population
Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: \<=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: \>=38 degrees Celsius. If values were unchanged (example: increase to \>=38 degrees Celsius to increase to \>=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature
Decrease to low
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature
Change to normal or no change
|
4 Participants
|
4 Participants
|
5 Participants
|
10 Participants
|
11 Participants
|
12 Participants
|
12 Participants
|
12 Participants
|
|
Part 2A: Number of Participants With Worst Case Change From Baseline in Body Temperature
Increase to high
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline (Day 1) and up to maximum 33 weeksPopulation: All Treated Population
Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date (Day 1). Change from Baseline was defined as post Baseline value minus Baseline value. Number of participants with worst case change from Baseline in body temperature is presented. Data was categorized as: 'decrease to low', 'increase to high' and 'change to normal or no change'; where low body temperature: \<=35 degrees Celsius, normal body temperature: 35 to 38 degrees Celsius and high body temperature: \>=38 degrees Celsius. If values were unchanged (example: increase to \>=38 degrees Celsius to increase to \>=38 degrees Celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to low' and 'increased to high' during post Baseline, so the percentages might not add to 100%.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature
Decrease to low
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature
Change to normal or no change
|
—
|
9 Participants
|
8 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Part 2B: Number of Participants With Worst Case Change From Baseline in Body Temperature
Increase to high
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population
A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant Electrocardiogram (ECG) Findings
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population. Only those participants with data available at the indicated data points were analyzed.
A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=4 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=3 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population. Only those participants with data available at the indicated data points were analyzed.
A 12-lead ECG was obtained after the participant had rested at least 10 minutes in a semi-recumbent or supine position during the study using ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with worst case post Baseline abnormal clinical significant ECG findings are presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=4 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=7 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=4 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG Findings
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population
ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or a partial response (PR) as the Best Overall Response (BOR), as assessed by the investigator per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter. PR: \>=30 percent (%) decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Objective Response Rate (ORR)
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
SECONDARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population. The efficacy outputs were presented according to planned study treatment. One participant in Part 2A was planned for 0.01mg, but received 0.003mg at first dose in error. One participant in Part 2A was planned for 0.003mg, but received 0.3mg at first dose in error. Hence, 'N' for the 'Part 2A: GSK3174998 0.01 mg/kg+Pembrolizumab 200 mg' arm is greater than that for the Participant Flow.
ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter. PR: \>=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=6 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=13 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Objective Response Rate (ORR)
|
0 Percentage of participants
|
0 Percentage of participants
|
17 Percentage of participants
|
0 Percentage of participants
|
25 Percentage of participants
|
8 Percentage of participants
|
8 Percentage of participants
|
0 Percentage of participants
|
SECONDARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population
ORR is defined as the percentage of participants achieving a confirmed CR or PR as the BOR, as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter. PR: \>=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Objective Response Rate (ORR)
|
—
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population
DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus stable disease (SD) \>=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter. PR: \>=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Disease Control Rate (DCR)
|
75 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
10 Percentage of participants
|
20 Percentage of participants
|
0 Percentage of participants
|
14 Percentage of participants
|
SECONDARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population. The efficacy outputs were presented according to planned study treatment. One participant in Part 2A was planned for 0.01mg, but received 0.003mg at first dose in error. One participant in Part 2A was planned for 0.003mg, but received 0.3mg at first dose in error. Hence, 'N' for the 'Part 2A: GSK3174998 0.01 mg/kg+Pembrolizumab 200 mg' arm is greater than that for the Participant Flow.
DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD \>=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter. PR: \>=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=6 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=13 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Disease Control Rate (DCR)
|
0 Percentage of participants
|
0 Percentage of participants
|
33 Percentage of participants
|
0 Percentage of participants
|
50 Percentage of participants
|
23 Percentage of participants
|
50 Percentage of participants
|
58 Percentage of participants
|
SECONDARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population
DCR is defined as the percentage of participants with a confirmed CR or PR at any time, plus SD \>=12 weeks as assessed by the investigator per RECIST v 1.1 criteria. CR: Disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter. PR: \>=30% decrease in tumor burden compared with Baseline in two observations at least 4 weeks apart. SD: 30% decrease in tumor burden compared with Baseline cannot be established nor 20% increase compared with nadir.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Disease Control Rate (DCR)
|
—
|
11 Percentage of participants
|
0 Percentage of participants
|
60 Percentage of participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusionPopulation: Pharmacokinetic Population consisted of all participants from the All Treated Population for whom a PK sample was obtained and analyzed. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for pharmacokinetic (PK) analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day85, 30minutes after EOI, n=0,0,1,4,3,2,2,3
|
294.788 Micrograms per milliliter
Standard Deviation 15.9947
|
—
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
1.246 Micrograms per milliliter
Standard Deviation 1.3975
|
9.421 Micrograms per milliliter
Standard Deviation 1.8598
|
32.824 Micrograms per milliliter
Standard Deviation 0.4611
|
82.402 Micrograms per milliliter
Standard Deviation 18.5192
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 8, n=1,1,8,10,10,3,7,4
|
108.278 Micrograms per milliliter
Standard Deviation 44.5563
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.122 Micrograms per milliliter
Standard Deviation 0.0926
|
0.678 Micrograms per milliliter
Standard Deviation 0.4251
|
1.932 Micrograms per milliliter
Standard Deviation 0.3732
|
9.675 Micrograms per milliliter
Standard Deviation 2.9619
|
32.974 Micrograms per milliliter
Standard Deviation 8.4840
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 1, predose, n=1,1,8,10,10,4,7,4
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.001 Micrograms per milliliter
Standard Deviation 0.0033
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 30minutes after EOI, n=1,1,8,10,10,4,7,4
|
277.615 Micrograms per milliliter
Standard Deviation 30.9564
|
0.044 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.181 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.893 Micrograms per milliliter
Standard Deviation 0.3505
|
2.958 Micrograms per milliliter
Standard Deviation 1.1359
|
6.091 Micrograms per milliliter
Standard Deviation 1.6075
|
23.224 Micrograms per milliliter
Standard Deviation 5.2813
|
77.500 Micrograms per milliliter
Standard Deviation 17.8619
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 4hour after EOI, n=1,1,8,10,9,4,7,4
|
243.701 Micrograms per milliliter
Standard Deviation 42.5698
|
0.021 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.140 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.809 Micrograms per milliliter
Standard Deviation 0.3205
|
2.668 Micrograms per milliliter
Standard Deviation 1.0513
|
5.615 Micrograms per milliliter
Standard Deviation 1.3647
|
21.533 Micrograms per milliliter
Standard Deviation 5.5070
|
70.603 Micrograms per milliliter
Standard Deviation 15.1388
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 24hour after EOI, n=1,1,6,10,9,4,7,4
|
191.862 Micrograms per milliliter
Standard Deviation 35.7293
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.083 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.564 Micrograms per milliliter
Standard Deviation 0.2508
|
2.080 Micrograms per milliliter
Standard Deviation 0.9446
|
4.954 Micrograms per milliliter
Standard Deviation 1.2600
|
17.645 Micrograms per milliliter
Standard Deviation 3.8210
|
59.143 Micrograms per milliliter
Standard Deviation 12.1864
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 14, n=1,1,8,9,10,3,7,4
|
80.909 Micrograms per milliliter
Standard Deviation 27.3394
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.022 Micrograms per milliliter
Standard Deviation 0.0412
|
0.190 Micrograms per milliliter
Standard Deviation 0.1577
|
1.205 Micrograms per milliliter
Standard Deviation 0.2799
|
5.303 Micrograms per milliliter
Standard Deviation 1.9430
|
21.705 Micrograms per milliliter
Standard Deviation 6.4334
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 22, predose, n=1,1,8,10,10,4,7,4
|
58.537 Micrograms per milliliter
Standard Deviation 17.2736
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.003 Micrograms per milliliter
Standard Deviation 0.0087
|
0.026 Micrograms per milliliter
Standard Deviation 0.0529
|
0.605 Micrograms per milliliter
Standard Deviation 0.2412
|
2.826 Micrograms per milliliter
Standard Deviation 2.1396
|
15.185 Micrograms per milliliter
Standard Deviation 4.1187
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 30minutes after EOI, n=1,1,8,10,10,4,7,4
|
321.132 Micrograms per milliliter
Standard Deviation 40.4375
|
0.043 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.174 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.619 Micrograms per milliliter
Standard Deviation 0.2229
|
2.579 Micrograms per milliliter
Standard Deviation 0.4762
|
7.256 Micrograms per milliliter
Standard Deviation 1.8199
|
25.859 Micrograms per milliliter
Standard Deviation 9.2995
|
81.115 Micrograms per milliliter
Standard Deviation 32.5472
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 4hour after EOI, n=1,1,8,10,9,4,7,4
|
306.585 Micrograms per milliliter
Standard Deviation 31.7702
|
0.038 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.149 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.523 Micrograms per milliliter
Standard Deviation 0.1963
|
2.301 Micrograms per milliliter
Standard Deviation 0.4088
|
6.519 Micrograms per milliliter
Standard Deviation 1.5717
|
22.905 Micrograms per milliliter
Standard Deviation 9.6502
|
82.690 Micrograms per milliliter
Standard Deviation 18.1793
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 24hour after EOI, n=1,0,6,9,9,4,7,4
|
260.830 Micrograms per milliliter
Standard Deviation 44.1526
|
0.012 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
—
|
0.319 Micrograms per milliliter
Standard Deviation 0.1676
|
1.711 Micrograms per milliliter
Standard Deviation 0.4435
|
4.933 Micrograms per milliliter
Standard Deviation 0.8727
|
17.869 Micrograms per milliliter
Standard Deviation 9.3910
|
72.801 Micrograms per milliliter
Standard Deviation 17.5925
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 29, n=0,1,8,10,10,4,7,4
|
153.655 Micrograms per milliliter
Standard Deviation 37.5871
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.037 Micrograms per milliliter
Standard Deviation 0.0663
|
0.380 Micrograms per milliliter
Standard Deviation 0.2882
|
2.243 Micrograms per milliliter
Standard Deviation 0.8667
|
8.654 Micrograms per milliliter
Standard Deviation 5.9929
|
42.013 Micrograms per milliliter
Standard Deviation 13.3448
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day43, 30minutes after EOI, n=0,1,6,7,9,3,5,3
|
302.882 Micrograms per milliliter
Standard Deviation 3.7341
|
—
|
0.267 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.547 Micrograms per milliliter
Standard Deviation 0.5929
|
2.130 Micrograms per milliliter
Standard Deviation 1.4403
|
7.373 Micrograms per milliliter
Standard Deviation 2.3810
|
30.602 Micrograms per milliliter
Standard Deviation 0.6521
|
95.775 Micrograms per milliliter
Standard Deviation 22.9300
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 36, n=0,1,7,9,9,4,6,4
|
111.545 Micrograms per milliliter
Standard Deviation 22.8298
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.013 Micrograms per milliliter
Standard Deviation 0.0313
|
0.115 Micrograms per milliliter
Standard Deviation 0.1114
|
1.227 Micrograms per milliliter
Standard Deviation 0.4101
|
6.428 Micrograms per milliliter
Standard Deviation 4.5933
|
31.093 Micrograms per milliliter
Standard Deviation 10.5909
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 43, predose, n=0,1,6,8,9,4,5,3
|
82.723 Micrograms per milliliter
Standard Deviation 26.1829
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.003 Micrograms per milliliter
Standard Deviation 0.0064
|
0.023 Micrograms per milliliter
Standard Deviation 0.0355
|
0.832 Micrograms per milliliter
Standard Deviation 0.5269
|
4.789 Micrograms per milliliter
Standard Deviation 3.2591
|
21.658 Micrograms per milliliter
Standard Deviation 8.9413
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 64, predose, n=0,1,5,5,7,4,4,3
|
76.602 Micrograms per milliliter
Standard Deviation 27.6046
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.023 Micrograms per milliliter
Standard Deviation 0.0520
|
0.014 Micrograms per milliliter
Standard Deviation 0.0206
|
1.097 Micrograms per milliliter
Standard Deviation 0.4744
|
5.747 Micrograms per milliliter
Standard Deviation 3.8915
|
23.922 Micrograms per milliliter
Standard Deviation 9.6447
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day64, 30minutes after EOI, n=0,0,5,5,7,4,4,2
|
312.277 Micrograms per milliliter
Standard Deviation 61.0388
|
—
|
—
|
0.339 Micrograms per milliliter
Standard Deviation 0.4499
|
1.154 Micrograms per milliliter
Standard Deviation 1.2985
|
7.952 Micrograms per milliliter
Standard Deviation 2.7538
|
21.941 Micrograms per milliliter
Standard Deviation 15.0801
|
98.410 Micrograms per milliliter
Standard Deviation 19.0269
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 85, predose, n=0,0,1,4,3,2,2,3
|
83.090 Micrograms per milliliter
Standard Deviation 31.8311
|
—
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.023 Micrograms per milliliter
Standard Deviation 0.0315
|
1.227 Micrograms per milliliter
Standard Deviation 0.7462
|
8.518 Micrograms per milliliter
Standard Deviation 0.6700
|
22.635 Micrograms per milliliter
Standard Deviation 3.1816
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day106, predose, n=0,0,1,1,2,2,1,2
|
94.359 Micrograms per milliliter
Standard Deviation 11.4639
|
—
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
1.323 Micrograms per milliliter
Standard Deviation 0.2234
|
8.497 Micrograms per milliliter
Standard Deviation 0.5922
|
19.047 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
|
Part 1: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day106, 30minutes after EOI, n=0,0,0,1,3,2,1,2
|
307.222 Micrograms per milliliter
Standard Deviation 3.5048
|
—
|
—
|
—
|
1.591 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
8.377 Micrograms per milliliter
Standard Deviation 0.3270
|
33.406 Micrograms per milliliter
Standard Deviation 6.3673
|
79.852 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusionPopulation: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=4 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 1, predose, n=4,5,9,10,11,11,12,4
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.928 Micrograms per milliliter
Standard Deviation 3.0764
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 30minutes after EOI, n=4,5,9,10,11,11,12,4
|
193.082 Micrograms per milliliter
Standard Deviation 30.6483
|
0.051 Micrograms per milliliter
Standard Deviation 0.0212
|
0.235 Micrograms per milliliter
Standard Deviation 0.0971
|
0.833 Micrograms per milliliter
Standard Deviation 0.5313
|
2.088 Micrograms per milliliter
Standard Deviation 0.8049
|
6.542 Micrograms per milliliter
Standard Deviation 2.1648
|
25.623 Micrograms per milliliter
Standard Deviation 6.4576
|
70.550 Micrograms per milliliter
Standard Deviation 16.4984
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 4hour after EOI, n=4,5,9,10,11,11,12,4
|
178.023 Micrograms per milliliter
Standard Deviation 20.6597
|
0.038 Micrograms per milliliter
Standard Deviation 0.0263
|
0.215 Micrograms per milliliter
Standard Deviation 0.0396
|
0.762 Micrograms per milliliter
Standard Deviation 0.4730
|
2.160 Micrograms per milliliter
Standard Deviation 1.0232
|
5.819 Micrograms per milliliter
Standard Deviation 1.6015
|
23.367 Micrograms per milliliter
Standard Deviation 4.5233
|
66.831 Micrograms per milliliter
Standard Deviation 17.5167
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 24hour after EOI, n=4,5,9,10,11,11,12,4
|
140.747 Micrograms per milliliter
Standard Deviation 9.5100
|
0.010 Micrograms per milliliter
Standard Deviation 0.0125
|
0.112 Micrograms per milliliter
Standard Deviation 0.0599
|
0.578 Micrograms per milliliter
Standard Deviation 0.4049
|
1.644 Micrograms per milliliter
Standard Deviation 0.7086
|
5.084 Micrograms per milliliter
Standard Deviation 1.7161
|
19.398 Micrograms per milliliter
Standard Deviation 5.6732
|
55.782 Micrograms per milliliter
Standard Deviation 13.0007
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 8, n=4,5,10,11,14,11,12,4
|
71.830 Micrograms per milliliter
Standard Deviation 14.1731
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.428 Micrograms per milliliter
Standard Deviation 0.9836
|
0.592 Micrograms per milliliter
Standard Deviation 0.3233
|
2.203 Micrograms per milliliter
Standard Deviation 0.7619
|
12.151 Micrograms per milliliter
Standard Deviation 8.5380
|
30.442 Micrograms per milliliter
Standard Deviation 8.6063
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 15, n=4,4,10,10,12,11,12,4
|
50.342 Micrograms per milliliter
Standard Deviation 12.5709
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.257 Micrograms per milliliter
Standard Deviation 0.7547
|
0.200 Micrograms per milliliter
Standard Deviation 0.1821
|
1.357 Micrograms per milliliter
Standard Deviation 0.7574
|
8.458 Micrograms per milliliter
Standard Deviation 8.3133
|
22.050 Micrograms per milliliter
Standard Deviation 6.8631
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 22, predose, n=3,2,10,10,12,10,12,3
|
31.882 Micrograms per milliliter
Standard Deviation 12.4466
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.106 Micrograms per milliliter
Standard Deviation 0.3359
|
0.080 Micrograms per milliliter
Standard Deviation 0.0880
|
0.626 Micrograms per milliliter
Standard Deviation 0.3716
|
6.912 Micrograms per milliliter
Standard Deviation 7.0973
|
16.354 Micrograms per milliliter
Standard Deviation 5.5789
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 30minutes after EOI, n=3,2,10,10,12,9,12,3
|
222.118 Micrograms per milliliter
Standard Deviation 45.7084
|
0.080 Micrograms per milliliter
Standard Deviation 0.0350
|
0.879 Micrograms per milliliter
Standard Deviation 0.8898
|
0.754 Micrograms per milliliter
Standard Deviation 0.4533
|
2.343 Micrograms per milliliter
Standard Deviation 0.5196
|
7.496 Micrograms per milliliter
Standard Deviation 2.7519
|
30.238 Micrograms per milliliter
Standard Deviation 4.8782
|
85.882 Micrograms per milliliter
Standard Deviation 16.2709
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 4hour after EOI, n=3,2,9,10,12,9,12,3
|
205.085 Micrograms per milliliter
Standard Deviation 26.1667
|
0.052 Micrograms per milliliter
Standard Deviation 0.0406
|
0.682 Micrograms per milliliter
Standard Deviation 0.6743
|
0.704 Micrograms per milliliter
Standard Deviation 0.4011
|
2.203 Micrograms per milliliter
Standard Deviation 0.4515
|
6.938 Micrograms per milliliter
Standard Deviation 2.6934
|
27.273 Micrograms per milliliter
Standard Deviation 6.0059
|
82.796 Micrograms per milliliter
Standard Deviation 16.8542
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 24hour after EOI, n=3,2,7,7,9,10,12,3
|
164.798 Micrograms per milliliter
Standard Deviation 36.7704
|
0.011 Micrograms per milliliter
Standard Deviation 0.0188
|
0.365 Micrograms per milliliter
Standard Deviation 0.3729
|
0.628 Micrograms per milliliter
Standard Deviation 0.3755
|
1.702 Micrograms per milliliter
Standard Deviation 0.3438
|
6.015 Micrograms per milliliter
Standard Deviation 2.6501
|
21.631 Micrograms per milliliter
Standard Deviation 8.6914
|
69.978 Micrograms per milliliter
Standard Deviation 13.9446
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 29, n=3,1,9,10,10,10,12,1
|
67.369 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.045 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.134 Micrograms per milliliter
Standard Deviation 0.2410
|
0.607 Micrograms per milliliter
Standard Deviation 0.3352
|
2.682 Micrograms per milliliter
Standard Deviation 1.5569
|
11.961 Micrograms per milliliter
Standard Deviation 5.5511
|
45.527 Micrograms per milliliter
Standard Deviation 14.7008
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 36, n=3,2,8,8,8,10,11,1
|
106.605 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.019 Micrograms per milliliter
Standard Deviation 0.0404
|
0.243 Micrograms per milliliter
Standard Deviation 0.2081
|
1.994 Micrograms per milliliter
Standard Deviation 1.2562
|
9.146 Micrograms per milliliter
Standard Deviation 4.7873
|
33.671 Micrograms per milliliter
Standard Deviation 10.9055
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 43, predose, n=3,3,7,7,8,9,12,1
|
74.088 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.071 Micrograms per milliliter
Standard Deviation 0.1213
|
0.950 Micrograms per milliliter
Standard Deviation 0.6068
|
7.207 Micrograms per milliliter
Standard Deviation 2.1852
|
24.578 Micrograms per milliliter
Standard Deviation 8.5351
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day43, 30minutes after EOI, n=3,3,7,7,8,8,12,1
|
377.078 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.071 Micrograms per milliliter
Standard Deviation 0.0156
|
0.229 Micrograms per milliliter
Standard Deviation 0.0379
|
0.496 Micrograms per milliliter
Standard Deviation 0.2657
|
1.922 Micrograms per milliliter
Standard Deviation 0.8919
|
7.639 Micrograms per milliliter
Standard Deviation 2.1641
|
28.433 Micrograms per milliliter
Standard Deviation 5.1446
|
94.463 Micrograms per milliliter
Standard Deviation 20.9570
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 64, predose, n=1,3,2,6,4,8,10,0
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.067 Micrograms per milliliter
Standard Deviation 0.1145
|
0.706 Micrograms per milliliter
Standard Deviation 0.8655
|
8.349 Micrograms per milliliter
Standard Deviation 2.7499
|
32.716 Micrograms per milliliter
Standard Deviation 11.1159
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day64, 30minutes after EOI, n=1,3,2,7,4,8,10,0
|
—
|
0.067 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.245 Micrograms per milliliter
Standard Deviation 0.0932
|
0.284 Micrograms per milliliter
Standard Deviation 0.4014
|
2.152 Micrograms per milliliter
Standard Deviation 1.3890
|
6.032 Micrograms per milliliter
Standard Deviation 3.2357
|
33.382 Micrograms per milliliter
Standard Deviation 5.0217
|
99.623 Micrograms per milliliter
Standard Deviation 25.2220
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 85, predose, n=0,3,0,5,5,7,8,0
|
—
|
—
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
—
|
0.115 Micrograms per milliliter
Standard Deviation 0.1528
|
0.938 Micrograms per milliliter
Standard Deviation 0.9332
|
10.323 Micrograms per milliliter
Standard Deviation 3.5051
|
35.166 Micrograms per milliliter
Standard Deviation 13.8402
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day85, 30minutes after EOI, n=0,3,0,5,5,7,8,0
|
—
|
—
|
0.228 Micrograms per milliliter
Standard Deviation 0.0996
|
—
|
2.275 Micrograms per milliliter
Standard Deviation 1.2464
|
7.734 Micrograms per milliliter
Standard Deviation 2.5853
|
34.982 Micrograms per milliliter
Standard Deviation 6.5978
|
100.514 Micrograms per milliliter
Standard Deviation 26.7950
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day106, predose, n=0,1,0,5,5,5,8,0
|
—
|
—
|
0.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
—
|
0.184 Micrograms per milliliter
Standard Deviation 0.1858
|
0.647 Micrograms per milliliter
Standard Deviation 0.8249
|
10.395 Micrograms per milliliter
Standard Deviation 5.5838
|
36.990 Micrograms per milliliter
Standard Deviation 16.0967
|
|
Part 2A: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day106, 30minutes after EOI, n=0,1,0,5,4,5,8,0
|
—
|
—
|
0.269 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
—
|
2.477 Micrograms per milliliter
Standard Deviation 0.8254
|
8.218 Micrograms per milliliter
Standard Deviation 3.9343
|
33.183 Micrograms per milliliter
Standard Deviation 6.7012
|
108.103 Micrograms per milliliter
Standard Deviation 29.3324
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusionPopulation: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion (EOI); anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=4 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day106, predose, n=1,2,2
|
—
|
1.714 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
0.800 Micrograms per milliliter
Standard Deviation 1.0858
|
1.015 Micrograms per milliliter
Standard Deviation 0.6750
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 1, predose, n=7,5,3
|
—
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 30minutes after EOI, n=7,6,4
|
—
|
6.132 Micrograms per milliliter
Standard Deviation 2.6768
|
5.668 Micrograms per milliliter
Standard Deviation 1.1752
|
7.618 Micrograms per milliliter
Standard Deviation 0.6794
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 4hour after EOI, n=7,6,4
|
—
|
5.229 Micrograms per milliliter
Standard Deviation 2.1553
|
5.383 Micrograms per milliliter
Standard Deviation 0.6932
|
6.638 Micrograms per milliliter
Standard Deviation 1.2259
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day1, 24hour after EOI, n=7,5,0
|
—
|
4.000 Micrograms per milliliter
Standard Deviation 1.7095
|
4.141 Micrograms per milliliter
Standard Deviation 1.0168
|
—
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 8, n=8,7,4
|
—
|
1.972 Micrograms per milliliter
Standard Deviation 0.3899
|
2.062 Micrograms per milliliter
Standard Deviation 0.7993
|
2.501 Micrograms per milliliter
Standard Deviation 0.6042
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 15, n=8,7,4
|
—
|
0.989 Micrograms per milliliter
Standard Deviation 0.3362
|
1.223 Micrograms per milliliter
Standard Deviation 0.5792
|
1.252 Micrograms per milliliter
Standard Deviation 0.3432
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 22, predose, n=8,7,4
|
—
|
0.401 Micrograms per milliliter
Standard Deviation 0.3015
|
0.646 Micrograms per milliliter
Standard Deviation 0.5756
|
0.444 Micrograms per milliliter
Standard Deviation 0.2856
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 30minutes after EOI, n=8,7,4
|
—
|
5.805 Micrograms per milliliter
Standard Deviation 0.8298
|
6.259 Micrograms per milliliter
Standard Deviation 1.3552
|
7.226 Micrograms per milliliter
Standard Deviation 0.8588
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 4hour after EOI, n=8,7,4
|
—
|
5.722 Micrograms per milliliter
Standard Deviation 1.5376
|
5.810 Micrograms per milliliter
Standard Deviation 1.4074
|
7.363 Micrograms per milliliter
Standard Deviation 1.0038
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day22, 24hour after EOI, n=4,2,4
|
—
|
4.531 Micrograms per milliliter
Standard Deviation 0.6357
|
2.070 Micrograms per milliliter
Standard Deviation 0.5224
|
5.850 Micrograms per milliliter
Standard Deviation 1.3604
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 29, n=9,8,4
|
—
|
1.715 Micrograms per milliliter
Standard Deviation 0.8979
|
2.201 Micrograms per milliliter
Standard Deviation 1.4063
|
2.070 Micrograms per milliliter
Standard Deviation 0.9160
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 36, n=7,6,4
|
—
|
0.871 Micrograms per milliliter
Standard Deviation 0.7222
|
1.597 Micrograms per milliliter
Standard Deviation 1.2560
|
1.124 Micrograms per milliliter
Standard Deviation 0.5805
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 43, predose, n=8,4,2
|
—
|
0.442 Micrograms per milliliter
Standard Deviation 0.4862
|
1.045 Micrograms per milliliter
Standard Deviation 1.0289
|
0.570 Micrograms per milliliter
Standard Deviation 0.6971
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day43, 30minutes after EOI, n=8,4,2
|
—
|
6.657 Micrograms per milliliter
Standard Deviation 1.1060
|
7.271 Micrograms per milliliter
Standard Deviation 2.0499
|
6.913 Micrograms per milliliter
Standard Deviation 2.3366
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 64, predose, n=4,3,2
|
—
|
0.726 Micrograms per milliliter
Standard Deviation 0.7935
|
1.520 Micrograms per milliliter
Standard Deviation 1.2083
|
0.663 Micrograms per milliliter
Standard Deviation 0.8153
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day64, 30minutes after EOI, n=4,3,2
|
—
|
7.496 Micrograms per milliliter
Standard Deviation 1.7948
|
7.480 Micrograms per milliliter
Standard Deviation 2.0226
|
8.172 Micrograms per milliliter
Standard Deviation 0.5517
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day 85, predose, n=2,3,2
|
—
|
0.976 Micrograms per milliliter
Standard Deviation 0.9973
|
1.631 Micrograms per milliliter
Standard Deviation 1.5426
|
0.711 Micrograms per milliliter
Standard Deviation 0.5122
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day85, 30minutes after EOI, n=2,3,2
|
—
|
10.245 Micrograms per milliliter
Standard Deviation 0.2669
|
8.920 Micrograms per milliliter
Standard Deviation 2.4241
|
9.208 Micrograms per milliliter
Standard Deviation 1.3270
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of GSK3174998 at Indicated Time Points
Day106, 30minutes after EOI, n=2,2,1
|
—
|
9.933 Micrograms per milliliter
Standard Deviation 1.9969
|
6.324 Micrograms per milliliter
Standard Deviation 1.9856
|
8.673 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 for all arms to allow calculation of AUC(0-tau).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=6 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=9 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=3 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK3174998
Cycle 1, n=0,0,6,10,9,3,7,4
|
2129.9 Day*micrograms per milliliter
Geometric Coefficient of Variation 30.4
|
—
|
—
|
2.9362 Day*micrograms per milliliter
Geometric Coefficient of Variation 56.6
|
11.272 Day*micrograms per milliliter
Geometric Coefficient of Variation 57.8
|
39.374 Day*micrograms per milliliter
Geometric Coefficient of Variation 17.5
|
175.09 Day*micrograms per milliliter
Geometric Coefficient of Variation 33.2
|
630.94 Day*micrograms per milliliter
Geometric Coefficient of Variation 23.7
|
|
Part 1: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK3174998
Cycle 2, n=0,0,2,7,9,2,4,3
|
2859.4 Day*micrograms per milliliter
Geometric Coefficient of Variation 16.7
|
—
|
—
|
2.2804 Day*micrograms per milliliter
Geometric Coefficient of Variation 102.7
|
8.7296 Day*micrograms per milliliter
Geometric Coefficient of Variation 62.8
|
46.093 Day*micrograms per milliliter
Geometric Coefficient of Variation 30.7
|
255.78 Day*micrograms per milliliter
Geometric Coefficient of Variation 12.5
|
866.23 Day*micrograms per milliliter
Geometric Coefficient of Variation 33.5
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 in all arms to allow calculation of AUC(0-tau).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=3 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=4 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=9 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=8 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: AUC(0-tau) of GSK3174998
Cycle 1, n=0,0,4,10,9,8,12,3
|
1465.8 Day*micrograms per milliliter
Geometric Coefficient of Variation 20.3
|
—
|
—
|
4.2333 Day*micrograms per milliliter
Geometric Coefficient of Variation 77.9
|
11.592 Day*micrograms per milliliter
Geometric Coefficient of Variation 42.4
|
40.936 Day*micrograms per milliliter
Geometric Coefficient of Variation 34.2
|
175.17 Day*micrograms per milliliter
Geometric Coefficient of Variation 32.6
|
605.22 Day*micrograms per milliliter
Geometric Coefficient of Variation 29.2
|
|
Part 2A: AUC(0-tau) of GSK3174998
Cycle 2, n=0,0,2,6,7,8,12,1
|
2801.8 Day*micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
—
|
—
|
4.0512 Day*micrograms per milliliter
Geometric Coefficient of Variation 64.9
|
10.862 Day*micrograms per milliliter
Geometric Coefficient of Variation 44.0
|
52.517 Day*micrograms per milliliter
Geometric Coefficient of Variation 78.9
|
271.67 Day*micrograms per milliliter
Geometric Coefficient of Variation 30.0
|
862.97 Day*micrograms per milliliter
Geometric Coefficient of Variation 30.8
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles). There were not enough samples with concentrations above lower limit of quantification to allow calculation of AUC(0-tau) for 0.003mg and 0.01mg arms in Cycles 1 and 2. There was not enough PK sampling in Cycles 3,4 and 5 in all arms to allow calculation of AUC(0-tau).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Day 43: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=7 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=6 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=4 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: AUC(0-tau) of GSK3174998
Cycle 1, n=7,6,4
|
—
|
38.781 Day*micrograms per milliliter
Geometric Coefficient of Variation 9.6
|
38.171 Day*micrograms per milliliter
Geometric Coefficient of Variation 43.4
|
46.544 Day*micrograms per milliliter
Geometric Coefficient of Variation 21.9
|
—
|
—
|
—
|
—
|
|
Part 2B: AUC(0-tau) of GSK3174998
Cycle 2, n=7,4,2
|
—
|
39.504 Day*micrograms per milliliter
Geometric Coefficient of Variation 31.6
|
41.838 Day*micrograms per milliliter
Geometric Coefficient of Variation 96.8
|
33.502 Day*micrograms per milliliter
Geometric Coefficient of Variation 57.0
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmax, Cycle 1, n=1,1,8,10,10,4,7,4
|
276.4 Micrograms per milliliter
Geometric Coefficient of Variation 10.7
|
0.04440 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.1814 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.8408 Micrograms per milliliter
Geometric Coefficient of Variation 43.1
|
2.808 Micrograms per milliliter
Geometric Coefficient of Variation 35.5
|
6.002 Micrograms per milliliter
Geometric Coefficient of Variation 24.0
|
22.70 Micrograms per milliliter
Geometric Coefficient of Variation 26.0
|
75.81 Micrograms per milliliter
Geometric Coefficient of Variation 22.9
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmax, Cycle 2, n=1,1,8,10,10,4,6,4
|
320.2 Micrograms per milliliter
Geometric Coefficient of Variation 12.1
|
0.04280 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.1737 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.5816 Micrograms per milliliter
Geometric Coefficient of Variation 40.9
|
2.539 Micrograms per milliliter
Geometric Coefficient of Variation 20.4
|
7.096 Micrograms per milliliter
Geometric Coefficient of Variation 25.8
|
24.13 Micrograms per milliliter
Geometric Coefficient of Variation 49.4
|
90.26 Micrograms per milliliter
Geometric Coefficient of Variation 21.9
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmax, Cycle 3, n=0,1,6,7,9,3,5,3
|
302.9 Micrograms per milliliter
Geometric Coefficient of Variation 1.2
|
—
|
0.2671 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.2532 Micrograms per milliliter
Geometric Coefficient of Variation 369.2
|
1.355 Micrograms per milliliter
Geometric Coefficient of Variation 206.1
|
7.011 Micrograms per milliliter
Geometric Coefficient of Variation 35.7
|
30.60 Micrograms per milliliter
Geometric Coefficient of Variation 2.1
|
93.67 Micrograms per milliliter
Geometric Coefficient of Variation 23.7
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmax, Cycle 4, n=0,0,3,4,7,4,4,2
|
309.3 Micrograms per milliliter
Geometric Coefficient of Variation 19.9
|
—
|
—
|
0.3112 Micrograms per milliliter
Geometric Coefficient of Variation 395.0
|
0.5338 Micrograms per milliliter
Geometric Coefficient of Variation 1632.6
|
7.573 Micrograms per milliliter
Geometric Coefficient of Variation 34.5
|
8.117 Micrograms per milliliter
Geometric Coefficient of Variation 2535.5
|
97.02 Micrograms per milliliter
Geometric Coefficient of Variation 19.7
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmax, Cycle 5, n=0,0,0,3,3,2,2,3
|
294.5 Micrograms per milliliter
Geometric Coefficient of Variation 5.5
|
—
|
—
|
—
|
1.024 Micrograms per milliliter
Geometric Coefficient of Variation 264.9
|
9.292 Micrograms per milliliter
Geometric Coefficient of Variation 20.9
|
32.82 Micrograms per milliliter
Geometric Coefficient of Variation 1.4
|
81.35 Micrograms per milliliter
Geometric Coefficient of Variation 23.0
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmin, Cycle 1, n=0,0,1,4,10,3,7,4
|
56.29 Micrograms per milliliter
Geometric Coefficient of Variation 34.8
|
—
|
—
|
0.02450 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.04138 Micrograms per milliliter
Geometric Coefficient of Variation 139.4
|
0.5417 Micrograms per milliliter
Geometric Coefficient of Variation 62.6
|
3.626 Micrograms per milliliter
Geometric Coefficient of Variation 35.4
|
14.73 Micrograms per milliliter
Geometric Coefficient of Variation 26.9
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmin, Cycle 2, n=0,0,1,3,9,3,5,3
|
79.63 Micrograms per milliliter
Geometric Coefficient of Variation 36.0
|
—
|
—
|
0.01570 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.05811 Micrograms per milliliter
Geometric Coefficient of Variation 50.0
|
0.6702 Micrograms per milliliter
Geometric Coefficient of Variation 86.3
|
6.353 Micrograms per milliliter
Geometric Coefficient of Variation 12.3
|
19.92 Micrograms per milliliter
Geometric Coefficient of Variation 51.3
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmin, Cycle 3, n=0,0,1,2,7,3,4,3
|
72.89 Micrograms per milliliter
Geometric Coefficient of Variation 41.5
|
—
|
—
|
0.1162 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.03436 Micrograms per milliliter
Geometric Coefficient of Variation 39.2
|
0.9979 Micrograms per milliliter
Geometric Coefficient of Variation 52.7
|
7.633 Micrograms per milliliter
Geometric Coefficient of Variation 10.9
|
22.57 Micrograms per milliliter
Geometric Coefficient of Variation 40.3
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmin, Cycle 4, n=0,0,0,2,3,2,2,3
|
78.37 Micrograms per milliliter
Geometric Coefficient of Variation 45.9
|
—
|
—
|
—
|
0.04153 Micrograms per milliliter
Geometric Coefficient of Variation 75.0
|
1.053 Micrograms per milliliter
Geometric Coefficient of Variation 81.8
|
8.504 Micrograms per milliliter
Geometric Coefficient of Variation 7.9
|
22.52 Micrograms per milliliter
Geometric Coefficient of Variation 14.2
|
|
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of GSK3174998
Cmin, Cycle 5, n=0,0,0,0,2,2,1,2
|
94.01 Micrograms per milliliter
Geometric Coefficient of Variation 12.2
|
—
|
—
|
—
|
—
|
1.313 Micrograms per milliliter
Geometric Coefficient of Variation 17.1
|
8.486 Micrograms per milliliter
Geometric Coefficient of Variation 7.0
|
19.05 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=4 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=9 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=9 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmin, Cycle 1, n=0,0,1,6,12,9,12,3
|
30.32 Micrograms per milliliter
Geometric Coefficient of Variation 40.1
|
—
|
—
|
1.062 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.1120 Micrograms per milliliter
Geometric Coefficient of Variation 77.4
|
0.5031 Micrograms per milliliter
Geometric Coefficient of Variation 90.6
|
5.971 Micrograms per milliliter
Geometric Coefficient of Variation 77.9
|
15.04 Micrograms per milliliter
Geometric Coefficient of Variation 52.1
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmin, Cycle 2, n=0,0,0,2,8,9,12,1
|
74.09 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
—
|
—
|
—
|
0.2482 Micrograms per milliliter
Geometric Coefficient of Variation 5.2
|
0.6783 Micrograms per milliliter
Geometric Coefficient of Variation 161.3
|
6.887 Micrograms per milliliter
Geometric Coefficient of Variation 33.9
|
22.94 Micrograms per milliliter
Geometric Coefficient of Variation 43.8
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmin, Cycle 3, n=0,0,0,3,4,8,10,0
|
—
|
—
|
—
|
—
|
0.09191 Micrograms per milliliter
Geometric Coefficient of Variation 148.0
|
0.2505 Micrograms per milliliter
Geometric Coefficient of Variation 667.3
|
7.900 Micrograms per milliliter
Geometric Coefficient of Variation 38.3
|
30.77 Micrograms per milliliter
Geometric Coefficient of Variation 40.4
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmin, Cycle 4, n=0,0,0,3,5,7,8,0
|
—
|
—
|
—
|
—
|
0.1536 Micrograms per milliliter
Geometric Coefficient of Variation 95.4
|
0.4313 Micrograms per milliliter
Geometric Coefficient of Variation 383.9
|
9.882 Micrograms per milliliter
Geometric Coefficient of Variation 31.8
|
32.44 Micrograms per milliliter
Geometric Coefficient of Variation 48.4
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmin, Cycle 5, n=0,0,0,3,4,5,8,0
|
—
|
—
|
—
|
—
|
0.2912 Micrograms per milliliter
Geometric Coefficient of Variation 42.9
|
0.3995 Micrograms per milliliter
Geometric Coefficient of Variation 407.8
|
9.244 Micrograms per milliliter
Geometric Coefficient of Variation 59.5
|
33.69 Micrograms per milliliter
Geometric Coefficient of Variation 51.6
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmax, Cycle 1, n=4,5,9,10,11,9,12,4
|
191.3 Micrograms per milliliter
Geometric Coefficient of Variation 16.0
|
0.05321 Micrograms per milliliter
Geometric Coefficient of Variation 37.3
|
0.2505 Micrograms per milliliter
Geometric Coefficient of Variation 23.6
|
0.6748 Micrograms per milliliter
Geometric Coefficient of Variation 95.1
|
2.446 Micrograms per milliliter
Geometric Coefficient of Variation 23.4
|
6.345 Micrograms per milliliter
Geometric Coefficient of Variation 30.8
|
23.84 Micrograms per milliliter
Geometric Coefficient of Variation 18.9
|
71.37 Micrograms per milliliter
Geometric Coefficient of Variation 24.1
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmax, Cycle 2, n=3,1,9,9,12,9,12,3
|
220.0 Micrograms per milliliter
Geometric Coefficient of Variation 19.5
|
0.07490 Micrograms per milliliter
Geometric Coefficient of Variation 43.7
|
0.2496 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.7805 Micrograms per milliliter
Geometric Coefficient of Variation 44.6
|
2.419 Micrograms per milliliter
Geometric Coefficient of Variation 17.8
|
7.129 Micrograms per milliliter
Geometric Coefficient of Variation 37.2
|
29.87 Micrograms per milliliter
Geometric Coefficient of Variation 16.8
|
86.21 Micrograms per milliliter
Geometric Coefficient of Variation 20.4
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmax, Cycle 3, n=3,3,6,7,8,8,12,1
|
377.1 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.06961 Micrograms per milliliter
Geometric Coefficient of Variation 23.1
|
0.2269 Micrograms per milliliter
Geometric Coefficient of Variation 16.0
|
0.5577 Micrograms per milliliter
Geometric Coefficient of Variation 31.4
|
1.614 Micrograms per milliliter
Geometric Coefficient of Variation 90.5
|
7.373 Micrograms per milliliter
Geometric Coefficient of Variation 29.2
|
28.02 Micrograms per milliliter
Geometric Coefficient of Variation 18.4
|
92.25 Micrograms per milliliter
Geometric Coefficient of Variation 23.4
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmax, Cycle 4, n=1,3,1,7,4,8,10,0
|
—
|
0.06740 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.2328 Micrograms per milliliter
Geometric Coefficient of Variation 0.2328
|
0.5677 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
1.565 Micrograms per milliliter
Geometric Coefficient of Variation 133.4
|
4.898 Micrograms per milliliter
Geometric Coefficient of Variation 107.0
|
33.06 Micrograms per milliliter
Geometric Coefficient of Variation 14.7
|
96.86 Micrograms per milliliter
Geometric Coefficient of Variation 25.2
|
|
Part 2A: Cmax and Cmin of GSK3174998
Cmax, Cycle 5, n=0,3,0,5,5,7,8,0
|
—
|
—
|
0.2095 Micrograms per milliliter
Geometric Coefficient of Variation 56.6
|
—
|
1.664 Micrograms per milliliter
Geometric Coefficient of Variation 161.3
|
7.427 Micrograms per milliliter
Geometric Coefficient of Variation 31.8
|
34.37 Micrograms per milliliter
Geometric Coefficient of Variation 21.3
|
97.28 Micrograms per milliliter
Geometric Coefficient of Variation 28.5
|
SECONDARY outcome
Timeframe: Days 1, 22: Pre-dose and within 30 minutes, 4 hours, 24 hours after end of GSK3174998 infusion; anytime on Days 8,15,29,36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of GSK3174998 were collected on Days 1, 22: Pre-dose and within 30 minutes, 4 hour, 24 hour after end of GSK3174998 infusion; anytime on Days 8, 15, 29 and 36; Days 43, 64, 85, 106: Pre-dose and within 30 minutes after end of GSK3174998 infusion. Each dosing cycle was of 21 days. PK parameters of GSK3174998 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=8 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=7 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=4 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmax, Cycle 1, n=6,6,4
|
—
|
6.921 Micrograms per milliliter
Geometric Coefficient of Variation 19.1
|
5.717 Micrograms per milliliter
Geometric Coefficient of Variation 17.4
|
7.596 Micrograms per milliliter
Geometric Coefficient of Variation 8.7
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmax, Cycle 2, n=8,7,4
|
—
|
6.114 Micrograms per milliliter
Geometric Coefficient of Variation 19.3
|
6.139 Micrograms per milliliter
Geometric Coefficient of Variation 21.9
|
7.398 Micrograms per milliliter
Geometric Coefficient of Variation 12.8
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmax, Cycle 3, n=8,4,2
|
—
|
6.574 Micrograms per milliliter
Geometric Coefficient of Variation 17.3
|
7.066 Micrograms per milliliter
Geometric Coefficient of Variation 27.9
|
6.712 Micrograms per milliliter
Geometric Coefficient of Variation 35.5
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmax, Cycle 4, n=4,3,2
|
—
|
7.352 Micrograms per milliliter
Geometric Coefficient of Variation 22.5
|
7.296 Micrograms per milliliter
Geometric Coefficient of Variation 28.1
|
8.162 Micrograms per milliliter
Geometric Coefficient of Variation 6.8
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmax, Cycle 5, n=2,3,2
|
—
|
10.24 Micrograms per milliliter
Geometric Coefficient of Variation 2.6
|
8.684 Micrograms per milliliter
Geometric Coefficient of Variation 29.5
|
9.160 Micrograms per milliliter
Geometric Coefficient of Variation 14.5
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmin, Cycle 1, n=7,5,4
|
—
|
0.3781 Micrograms per milliliter
Geometric Coefficient of Variation 81.6
|
0.7925 Micrograms per milliliter
Geometric Coefficient of Variation 68.4
|
0.3823 Micrograms per milliliter
Geometric Coefficient of Variation 69.5
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmin, Cycle 2, n=7,3,2
|
—
|
0.3082 Micrograms per milliliter
Geometric Coefficient of Variation 187.9
|
1.092 Micrograms per milliliter
Geometric Coefficient of Variation 123.1
|
0.2857 Micrograms per milliliter
Geometric Coefficient of Variation 552.6
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmin, Cycle 3, n=3,3,2
|
—
|
0.7464 Micrograms per milliliter
Geometric Coefficient of Variation 117.5
|
0.9898 Micrograms per milliliter
Geometric Coefficient of Variation 225.3
|
0.3280 Micrograms per milliliter
Geometric Coefficient of Variation 577.1
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmin, Cycle 4, n=2,3,2
|
—
|
0.6753 Micrograms per milliliter
Geometric Coefficient of Variation 207.0
|
0.6852 Micrograms per milliliter
Geometric Coefficient of Variation 947.6
|
0.6114 Micrograms per milliliter
Geometric Coefficient of Variation 93.9
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmax and Cmin of GSK3174998
Cmin, Cycle 5, n=1,2,2
|
—
|
1.714 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
0.2250 Micrograms per milliliter
Geometric Coefficient of Variation 4329.5
|
0.8955 Micrograms per milliliter
Geometric Coefficient of Variation 82.7
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22, 64, 106Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion (EOPI); anytime on Days 8,15; Pre-dose on Days 22, 64, 106.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=4 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=10 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 1, predose, n=5,4,7,9,10,7,12,3
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
4.414 Micrograms per milliliter
Standard Deviation 11.6791
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.404 Micrograms per milliliter
Standard Deviation 1.2776
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
0.008 Micrograms per milliliter
Standard Deviation 0.0284
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day1, 30minutes after EOPI, n=5,1,8,6,8,7,10,4
|
65.100 Micrograms per milliliter
Standard Deviation 15.6721
|
40.860 Micrograms per milliliter
Standard Deviation 28.8970
|
41.000 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
72.588 Micrograms per milliliter
Standard Deviation 38.0995
|
62.983 Micrograms per milliliter
Standard Deviation 30.3605
|
59.175 Micrograms per milliliter
Standard Deviation 24.1666
|
75.857 Micrograms per milliliter
Standard Deviation 21.3825
|
66.100 Micrograms per milliliter
Standard Deviation 15.2560
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 8, n=5,4,10,11,14,12,12,4
|
34.025 Micrograms per milliliter
Standard Deviation 11.7196
|
20.340 Micrograms per milliliter
Standard Deviation 6.0719
|
29.600 Micrograms per milliliter
Standard Deviation 8.7882
|
33.850 Micrograms per milliliter
Standard Deviation 13.1268
|
27.618 Micrograms per milliliter
Standard Deviation 10.6709
|
30.757 Micrograms per milliliter
Standard Deviation 13.6721
|
35.600 Micrograms per milliliter
Standard Deviation 16.0615
|
32.792 Micrograms per milliliter
Standard Deviation 9.0537
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day1, 24hour after EOPI, n=5,4,10,8,10,12,12,4
|
48.900 Micrograms per milliliter
Standard Deviation 15.1969
|
44.140 Micrograms per milliliter
Standard Deviation 10.7050
|
56.675 Micrograms per milliliter
Standard Deviation 17.3734
|
65.230 Micrograms per milliliter
Standard Deviation 21.4209
|
50.463 Micrograms per milliliter
Standard Deviation 19.1378
|
53.810 Micrograms per milliliter
Standard Deviation 32.8301
|
54.442 Micrograms per milliliter
Standard Deviation 17.3552
|
51.842 Micrograms per milliliter
Standard Deviation 16.3551
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 15, n=5,4,10,9,13,12,11,4
|
25.175 Micrograms per milliliter
Standard Deviation 11.0852
|
14.560 Micrograms per milliliter
Standard Deviation 4.1531
|
21.575 Micrograms per milliliter
Standard Deviation 8.7332
|
25.020 Micrograms per milliliter
Standard Deviation 10.7905
|
21.611 Micrograms per milliliter
Standard Deviation 7.3849
|
21.369 Micrograms per milliliter
Standard Deviation 10.9198
|
26.525 Micrograms per milliliter
Standard Deviation 16.4784
|
25.773 Micrograms per milliliter
Standard Deviation 5.3967
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 22, predose, n=5,3,9,10,11,11,12,3
|
18.567 Micrograms per milliliter
Standard Deviation 10.6679
|
12.192 Micrograms per milliliter
Standard Deviation 3.4140
|
12.333 Micrograms per milliliter
Standard Deviation 1.5177
|
17.610 Micrograms per milliliter
Standard Deviation 9.7207
|
17.892 Micrograms per milliliter
Standard Deviation 6.6164
|
18.245 Micrograms per milliliter
Standard Deviation 12.8696
|
19.336 Micrograms per milliliter
Standard Deviation 13.4661
|
18.067 Micrograms per milliliter
Standard Deviation 5.2824
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 106, predose, n=1,1,0,6,5,5,8,0
|
—
|
18.500 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
28.100 Micrograms per milliliter
Standard Deviation NA
Standard deviation could not be calculated due to single participant
|
—
|
40.150 Micrograms per milliliter
Standard Deviation 14.0395
|
45.420 Micrograms per milliliter
Standard Deviation 20.7985
|
41.400 Micrograms per milliliter
Standard Deviation 17.4579
|
42.850 Micrograms per milliliter
Standard Deviation 17.0662
|
|
Part 2A: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 64, predose, n=3,3,2,6,5,8,10,0
|
—
|
22.433 Micrograms per milliliter
Standard Deviation 6.7678
|
30.133 Micrograms per milliliter
Standard Deviation 8.5008
|
38.550 Micrograms per milliliter
Standard Deviation 13.9300
|
26.560 Micrograms per milliliter
Standard Deviation 14.4486
|
30.720 Micrograms per milliliter
Standard Deviation 8.1940
|
37.000 Micrograms per milliliter
Standard Deviation 14.0108
|
33.640 Micrograms per milliliter
Standard Deviation 11.8732
|
SECONDARY outcome
Timeframe: Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22, 64, 106Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of pembrolizumab were collected on Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22, 64, 106.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 1, predose, n=8,8,5
|
—
|
3.341 Micrograms per milliliter
Standard Deviation 5.7855
|
0.000 Micrograms per milliliter
Standard Deviation 0.0000
|
11.940 Micrograms per milliliter
Standard Deviation 7.3057
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day1, 30minutes after EOPI, n=8,6,3
|
—
|
58.650 Micrograms per milliliter
Standard Deviation 12.5860
|
66.600 Micrograms per milliliter
Standard Deviation 15.4104
|
68.633 Micrograms per milliliter
Standard Deviation 7.2473
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day1, 24hour after EOPI, n=8,5,0
|
—
|
46.800 Micrograms per milliliter
Standard Deviation 12.7711
|
49.960 Micrograms per milliliter
Standard Deviation 7.3228
|
—
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 8, n=9,8,5
|
—
|
24.178 Micrograms per milliliter
Standard Deviation 10.0888
|
26.125 Micrograms per milliliter
Standard Deviation 7.6333
|
33.800 Micrograms per milliliter
Standard Deviation 7.5931
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 15, n=9,7,5
|
—
|
18.800 Micrograms per milliliter
Standard Deviation 8.8255
|
19.343 Micrograms per milliliter
Standard Deviation 7.3968
|
25.280 Micrograms per milliliter
Standard Deviation 5.7712
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 22, predose, n=9,7,4
|
—
|
13.458 Micrograms per milliliter
Standard Deviation 6.4173
|
15.180 Micrograms per milliliter
Standard Deviation 6.4652
|
18.775 Micrograms per milliliter
Standard Deviation 4.7479
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 64, predose, n=4,3,3
|
—
|
23.775 Micrograms per milliliter
Standard Deviation 8.2754
|
43.900 Micrograms per milliliter
Standard Deviation 12.1520
|
22.800 Micrograms per milliliter
Standard Deviation 6.0902
|
—
|
—
|
—
|
—
|
|
Part 2B: Plasma Concentrations of Pembrolizumab at Indicated Time Points
Day 106, predose, n=2,3,3
|
—
|
23.750 Micrograms per milliliter
Standard Deviation 10.6773
|
44.200 Micrograms per milliliter
Standard Deviation 24.5514
|
23.867 Micrograms per milliliter
Standard Deviation 10.1535
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. There were not enough PK sampling in Cycles 3 and 5 to allow calculation of AUC (0-tau).
Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=3 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=3 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=3 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=8 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=8 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: AUC(0-tau) of Pembrolizumab
|
703.61 Day*micrograms per milliliter
Geometric Coefficient of Variation 27.1
|
402.11 Day*micrograms per milliliter
Geometric Coefficient of Variation 43.3
|
561.35 Day*micrograms per milliliter
Geometric Coefficient of Variation 34.2
|
616.43 Day*micrograms per milliliter
Geometric Coefficient of Variation 43.7
|
581.61 Day*micrograms per milliliter
Geometric Coefficient of Variation 34.1
|
528.06 Day*micrograms per milliliter
Geometric Coefficient of Variation 33.4
|
639.86 Day*micrograms per milliliter
Geometric Coefficient of Variation 44.8
|
657.22 Day*micrograms per milliliter
Geometric Coefficient of Variation 22.5
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. There were not enough PK sampling in Cycles 3 and 5 to allow calculation of AUC (0-tau).
Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=6 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=6 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=1 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: AUC(0-tau) of Pembrolizumab
|
—
|
470.80 Day*micrograms per milliliter
Geometric Coefficient of Variation 31.5
|
546.97 Day*micrograms per milliliter
Geometric Coefficient of Variation 29.1
|
487.40 Day*micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. Post-dose samples were collected in Cycle 1 only and were not collected in Cycles 3 and 5 to calculate Cmax.
Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=3 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=6 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=6 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Cmax of Pembrolizumab
|
63.65 Micrograms per milliliter
Geometric Coefficient of Variation 25.1
|
51.83 Micrograms per milliliter
Geometric Coefficient of Variation 48.5
|
41.00 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
79.00 Micrograms per milliliter
Geometric Coefficient of Variation 34.8
|
57.00 Micrograms per milliliter
Geometric Coefficient of Variation 52.7
|
60.20 Micrograms per milliliter
Geometric Coefficient of Variation 36.2
|
72.73 Micrograms per milliliter
Geometric Coefficient of Variation 34.2
|
64.66 Micrograms per milliliter
Geometric Coefficient of Variation 22.0
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed. Post-dose samples were collected in Cycle 1 only and were not collected in Cycles 3 and 5 to calculate Cmax.
Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15, Pre-dose on Day 22 (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=6 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=6 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=1 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Cmax of Pembrolizumab
|
—
|
56.03 Micrograms per milliliter
Geometric Coefficient of Variation 19.6
|
65.32 Micrograms per milliliter
Geometric Coefficient of Variation 21.1
|
64.60 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=3 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=3 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=9 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Cmin of Pembrolizumab
Cycle 1, n=5,3,9,10,11,11,12,3
|
16.78 Micrograms per milliliter
Geometric Coefficient of Variation 57.6
|
11.85 Micrograms per milliliter
Geometric Coefficient of Variation 26.8
|
12.27 Micrograms per milliliter
Geometric Coefficient of Variation 12.6
|
15.52 Micrograms per milliliter
Geometric Coefficient of Variation 56.6
|
16.70 Micrograms per milliliter
Geometric Coefficient of Variation 42.6
|
15.81 Micrograms per milliliter
Geometric Coefficient of Variation 54.5
|
16.86 Micrograms per milliliter
Geometric Coefficient of Variation 52.2
|
17.39 Micrograms per milliliter
Geometric Coefficient of Variation 29.6
|
|
Part 2A: Cmin of Pembrolizumab
Cycle 3, n=3,3,2,6,5,8,10,0
|
—
|
21.71 Micrograms per milliliter
Geometric Coefficient of Variation 32.7
|
29.40 Micrograms per milliliter
Geometric Coefficient of Variation 27.1
|
37.27 Micrograms per milliliter
Geometric Coefficient of Variation 38.3
|
22.06 Micrograms per milliliter
Geometric Coefficient of Variation 85.1
|
29.93 Micrograms per milliliter
Geometric Coefficient of Variation 25.3
|
34.41 Micrograms per milliliter
Geometric Coefficient of Variation 44.6
|
32.02 Micrograms per milliliter
Geometric Coefficient of Variation 33.2
|
|
Part 2A: Cmin of Pembrolizumab
Cycle 5, n=1,1,0,6,5,5,8,0
|
—
|
18.50 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
28.10 Micrograms per milliliter
Geometric Coefficient of Variation NA
Geometric coefficient of variation could not be calculated due to single participant
|
—
|
37.73 Micrograms per milliliter
Geometric Coefficient of Variation 42.2
|
41.02 Micrograms per milliliter
Geometric Coefficient of Variation 57.0
|
38.13 Micrograms per milliliter
Geometric Coefficient of Variation 49.7
|
39.38 Micrograms per milliliter
Geometric Coefficient of Variation 49.6
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after end of pembrolizumab infusion; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days)Population: Pharmacokinetic Population. Only those participants with data available at the indicated data points were analyzed (represented by n=X in category titles).
Blood samples for PK analysis of pembrolizumab were collected on Cycle 1 Day 1: Pre-dose and within 30 minutes, 24 hours after EOPI; anytime on Days 8,15; Pre-dose on Days 22; Cycle 3 (Day 64), Cycle 5 (Day 106) (each dosing cycle was of 21 days). PK parameters of pembrolizumab were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=7 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=4 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Cmin of Pembrolizumab
Cycle 1, n=9,7,4
|
—
|
12.30 Micrograms per milliliter
Geometric Coefficient of Variation 45.9
|
13.88 Micrograms per milliliter
Geometric Coefficient of Variation 50.3
|
18.22 Micrograms per milliliter
Geometric Coefficient of Variation 30.3
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmin of Pembrolizumab
Cycle 3, n=4,3,3
|
—
|
22.78 Micrograms per milliliter
Geometric Coefficient of Variation 34.2
|
42.86 Micrograms per milliliter
Geometric Coefficient of Variation 26.9
|
22.28 Micrograms per milliliter
Geometric Coefficient of Variation 26.6
|
—
|
—
|
—
|
—
|
|
Part 2B: Cmin of Pembrolizumab
Cycle 5, n=2,3,3
|
—
|
22.52 Micrograms per milliliter
Geometric Coefficient of Variation 49.2
|
39.78 Micrograms per milliliter
Geometric Coefficient of Variation 61.3
|
22.52 Micrograms per milliliter
Geometric Coefficient of Variation 43.1
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to maximum 39 weeksPopulation: All Treated Population
Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point determined during assay validation. Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=1 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=1 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=8 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Positive Antidrug Antibodies (ADAs) Against GSK3174998
|
0 Participants
|
0 Participants
|
0 Participants
|
6 Participants
|
7 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population. Only those participants with data available at the indicated data points were analyzed.
Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=5 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=9 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=14 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=12 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Positive ADAs Against GSK3174998
|
0 Participants
|
2 Participants
|
2 Participants
|
6 Participants
|
8 Participants
|
5 Participants
|
4 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population. Only those participants with data available at the indicated data points were analyzed.
Serum samples were collected for the determination of anti-GSK3174998 antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a GSK3174998 bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with GSK3174998 that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-GSK3174998 antibodies results at any visit during the study have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=7 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2B: Number of Participants With Positive ADAs Against GSK3174998
|
—
|
4 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to maximum 105 weeksPopulation: All Treated Population. Only those participants with data available at the indicated data points were analyzed.
Serum samples were collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps. The presence of treatment emergent ADA was determined using a pembrolizumab bridging style ADA assay with a bio-analytically determined cut-point (determined during assay validation). Samples taken after dosing with pembrolizumab that had a value at or above the cut-point was considered treatment-emergent ADA-positive. These ADA positive samples were further evaluated in a confirmatory assay, and confirmed positive samples were further characterized by assessment of titer. Number of participants with confirmed positive anti-pembrolizumab antibodies results at any visit during the study have been presented.
Outcome measures
| Measure |
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=3 Participants
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=5 Participants
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=4 Participants
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=9 Participants
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 Participants
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=9 Participants
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=11 Participants
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=8 Participants
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
|---|---|---|---|---|---|---|---|---|
|
Part 2A: Number of Participants With Positive ADAs Against Pembrolizumab
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to maximum 33 weeksPopulation: All Treated Population. Data for this outcome measure was not collected as ADA samples were not collected in Part 2B.
Serum samples were planned to be collected for the determination of anti-pembrolizumab antibodies using binding ADA assay method using a tiered testing schema: screening, confirmation and titration steps.
Outcome measures
Outcome data not reported
Adverse Events
Part 1: GSK3174998 0.003 mg/kg
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
Part 1: GSK3174998 0.01 mg/kg
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Part 1: GSK3174998 0.03 mg/kg
Serious events: 3 serious events
Other events: 8 other events
Deaths: 6 deaths
Part 1: GSK3174998 0.1 mg/kg
Serious events: 7 serious events
Other events: 10 other events
Deaths: 9 deaths
Part 1: GSK3174998 0.3 mg/kg
Serious events: 2 serious events
Other events: 10 other events
Deaths: 6 deaths
Part 1: GSK3174998 1.0 mg/kg
Serious events: 1 serious events
Other events: 4 other events
Deaths: 2 deaths
Part 1: GSK3174998 3.0 mg/kg
Serious events: 2 serious events
Other events: 7 other events
Deaths: 5 deaths
Part 1: GSK3174998 10.0 mg/kg
Serious events: 1 serious events
Other events: 4 other events
Deaths: 2 deaths
Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg
Serious events: 1 serious events
Other events: 5 other events
Deaths: 4 deaths
Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg
Serious events: 1 serious events
Other events: 5 other events
Deaths: 4 deaths
Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg
Serious events: 6 serious events
Other events: 10 other events
Deaths: 7 deaths
Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg
Serious events: 4 serious events
Other events: 12 other events
Deaths: 9 deaths
Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg
Serious events: 4 serious events
Other events: 13 other events
Deaths: 9 deaths
Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg
Serious events: 4 serious events
Other events: 12 other events
Deaths: 6 deaths
Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg
Serious events: 2 serious events
Other events: 12 other events
Deaths: 5 deaths
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
Serious events: 2 serious events
Other events: 4 other events
Deaths: 4 deaths
Part 2B: Melanoma Cohort
Serious events: 1 serious events
Other events: 9 other events
Deaths: 6 deaths
Part 2B: Soft Tissue Sarcoma Cohort
Serious events: 2 serious events
Other events: 8 other events
Deaths: 4 deaths
Part 2B: NSCLC Cohort
Serious events: 1 serious events
Other events: 4 other events
Deaths: 2 deaths
Serious adverse events
| Measure |
Part 1: GSK3174998 0.003 mg/kg
n=1 participants at risk
Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.
|
Part 1: GSK3174998 0.01 mg/kg
n=1 participants at risk
Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.
|
Part 1: GSK3174998 0.03 mg/kg
n=8 participants at risk
Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 participants at risk
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 participants at risk
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 participants at risk
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 participants at risk
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 10.0 mg/kg
n=4 participants at risk
Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.
|
Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg
n=5 participants at risk
Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg
n=5 participants at risk
Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg
n=10 participants at risk
Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg
n=12 participants at risk
Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg
n=14 participants at risk
Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg
n=12 participants at risk
Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg
n=12 participants at risk
Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 participants at risk
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 participants at risk
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 participants at risk
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 participants at risk
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Hydronephrosis
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Cardiac disorders
Myocarditis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Pituitary haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Colonic fistula
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Asthenia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Fatigue
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Malaise
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Pyrexia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Device related infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
21.4%
3/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Urosepsis
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Dislocation of vertebra
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pituitary gland
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Radicular pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Organising pneumonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal stenosis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Superior vena cava syndrome
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
Other adverse events
| Measure |
Part 1: GSK3174998 0.003 mg/kg
n=1 participants at risk
Participants received intravenous (IV) dose of GSK3174998 0.003 milligram per kilogram (mg/kg) every 3 weeks (wks) in Part 1.
|
Part 1: GSK3174998 0.01 mg/kg
n=1 participants at risk
Participants received IV dose of GSK3174998 0.01 mg/kg every 3 weeks (Q3W) in Part 1.
|
Part 1: GSK3174998 0.03 mg/kg
n=8 participants at risk
Participants received IV dose of GSK3174998 0.03 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.1 mg/kg
n=10 participants at risk
Participants received IV dose of GSK3174998 0.1 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 0.3 mg/kg
n=10 participants at risk
Participants received IV dose of GSK3174998 0.3 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 1.0 mg/kg
n=4 participants at risk
Participants received IV dose of GSK3174998 1.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 3.0 mg/kg
n=7 participants at risk
Participants received IV dose of GSK3174998 3.0 mg/kg Q3W in Part 1.
|
Part 1: GSK3174998 10.0 mg/kg
n=4 participants at risk
Participants received IV dose of GSK3174998 10.0 mg/kg Q3W in Part 1.
|
Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg
n=5 participants at risk
Participants received IV dose of GSK3174998 0.003 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg
n=5 participants at risk
Participants received IV dose of GSK3174998 0.01 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg
n=10 participants at risk
Participants received IV dose of GSK3174998 0.03 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg
n=12 participants at risk
Participants received IV dose of GSK3174998 0.1 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg
n=14 participants at risk
Participants received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg
n=12 participants at risk
Participants received IV dose of GSK3174998 1.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg
n=12 participants at risk
Participants received IV dose of GSK3174998 3.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg
n=4 participants at risk
Participants received IV dose of GSK3174998 10.0 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2A.
|
Part 2B: Melanoma Cohort
n=9 participants at risk
Participants with melanoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: Soft Tissue Sarcoma Cohort
n=8 participants at risk
Participants with soft tissue sarcoma were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
Part 2B: NSCLC Cohort
n=5 participants at risk
Participants with non-small cell lung cancer (NSCLC) were included in this cohort and received IV dose of GSK3174998 0.3 mg/kg + pembrolizumab 200 mg IV Q3W in Part 2B.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Cardiac disorders
Cardiovascular disorder
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Congenital, familial and genetic disorders
Hereditary non-polyposis colorectal cancer syndrome
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Ear and labyrinth disorders
Middle ear inflammation
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Diabetes insipidus
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Hypopituitarism
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Endocrine disorders
Thyroiditis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Eye disorders
Cataract
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Eye disorders
Dry eye
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Eye disorders
Ocular hypertension
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
2/4 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
2/4 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 6 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
21.4%
3/14 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
2/4 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
4/8 • Number of events 11 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
21.4%
3/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
21.4%
3/14 • Number of events 7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
41.7%
5/12 • Number of events 5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
33.3%
3/9 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Oesophageal pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Subileus
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Asthenia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
2/4 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Axillary pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Chest pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Chills
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Fatigue
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
4/8 • Number of events 8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
33.3%
4/12 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
35.7%
5/14 • Number of events 6 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
33.3%
4/12 • Number of events 6 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
44.4%
4/9 • Number of events 6 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Hernia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Influenza like illness
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Localised oedema
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Malaise
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Oedema
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Oedema peripheral
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Peripheral swelling
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Pyrexia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
General disorders
Swelling
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Hepatobiliary disorders
Hepatocellular injury
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Cystitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Ear infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
37.5%
3/8 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Herpes virus infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Mastitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Oral fungal infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Otitis media
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Pulpitis dental
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Pyelitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Rash pustular
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Sepsis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Skin infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Injury, poisoning and procedural complications
Sunburn
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
22.2%
2/9 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Amylase
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Amylase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
22.2%
2/9 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood creatinine increased
|
100.0%
1/1 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood testosterone decreased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Lipase increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Platelet count decreased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Troponin increased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
Weight decreased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
4/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
33.3%
4/12 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
4/14 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyperlipasaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
21.4%
3/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
3/12 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
50.0%
2/4 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Joint stiffness
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
22.2%
2/9 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Bladder spasm
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Balance disorder
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Head discomfort
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
2/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Post-traumatic headache
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Syncope
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Nervous system disorders
Tremor
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Adjustment disorder
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Depression
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Disorientation
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Breast pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Breast swelling
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Oedema genital
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Reproductive system and breast disorders
Vaginal ulceration
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Aphonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
30.0%
3/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
2/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Increased upper airway secretion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Organising pneumonia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal discomfort
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
4/10 • Number of events 4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
28.6%
2/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus disorder
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
100.0%
1/1 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Erythema annulare
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Hair colour changes
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Macule
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Onycholysis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
22.2%
2/9 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
2/14 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 3 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
16.7%
2/12 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Skin atrophy
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Skin mass
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Skin tightness
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Angiopathy
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
20.0%
1/5 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Embolism
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Flushing
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Hot flush
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
14.3%
1/7 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
12.5%
1/8 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
40.0%
2/5 • Number of events 2 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
11.1%
1/9 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
8.3%
1/12 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
7.1%
1/14 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Phlebitis
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
10.0%
1/10 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
|
Vascular disorders
Raynaud's phenomenon
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/7 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
25.0%
1/4 • Number of events 1 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/10 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/14 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/12 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/4 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/9 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/8 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
0.00%
0/5 • Up to 39 weeks in Part 1; Up to 105 weeks in Part 2A; Up to 33 weeks in Part 2B
All-cause mortality, SAEs and non-SAEs were collected for All Treated Population which comprised of all participants who received at least one dose of GSK3174998.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER